TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06067009

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ImPart-Multi - IMproving the decisional PARTnership of Chronic Kidney Disease Dyads with concurrent metabolic disease
Description: ImPart-Multi is a psychoeducational, decision support training program, designed to impact Black chronic kidney disease patients with concurrent metabolic disease and their care partners' ability to 1. contemplate the decision needed, 2. request resources/support, and 3. make an informed patient-centered decision. Participants will participate in either communication training, social support effectiveness training, or a combination of both.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ImPart-Multi - IMproving the decisional PARTnership of Chronic Kidney Disease Dyads with concurrent metabolic disease
Description: ImPart-Multi is a psychoeducational, decision support training program, designed to impact Black chronic kidney disease patients with concurrent metabolic disease and their care partners' ability to 1. contemplate the decision needed, 2. request resources/support, and 3. make an informed patient-centered decision. Participants will participate in either communication training, social support effectiveness training, or a combination of both.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ImPart-Multi - IMproving the decisional PARTnership of Chronic Kidney Disease Dyads with concurrent metabolic disease
Description: ImPart-Multi is a psychoeducational, decision support training program, designed to impact Black chronic kidney disease patients with concurrent metabolic disease and their care partners' ability to 1. contemplate the decision needed, 2. request resources/support, and 3. make an informed patient-centered decision. Participants will participate in either communication training, social support effectiveness training, or a combination of both.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: ImPart-Multi - IMproving the decisional PARTnership of Chronic Kidney Disease Dyads with concurrent metabolic disease
Description: ImPart-Multi is a psychoeducational, decision support training program, designed to impact Black chronic kidney disease patients with concurrent metabolic disease and their care partners' ability to 1. contemplate the decision needed, 2. request resources/support, and 3. make an informed patient-centered decision. Participants will participate in either communication training, social support effectiveness training, or a combination of both.
Study: NCT04759404

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Deep Oscillation Treatment
Description: Deep oscillation to the lumbar region and stretching and strengthening exercise for waist, back and abdominal

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Myofascial Release Treatment
Description: Myofascial release to the lumbar region and stretching and strengthening exercise for waist, back and abdominal
Study: NCT05973669

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MED-EL Remote Care
Description: Remote cochlear implant support
Study: NCT06378866

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone
Description: Given abiraterone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apalutamide
Description: Given apalutamide

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Scan
Description: Undergo bone scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darolutamide
Description: Given darolutamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Degarelix
Description: Given degarelix

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide
Description: Given enzalutamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Goserelin
Description: Given goserelin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Histrelin
Description: Given histrelin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide
Description: Given leuprolide

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Observation
Description: Undergo watchful waiting

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Observation
Description: Undergo watchful waiting

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Given prednisone

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06748053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered.
Study: NCT06378866

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Relugolix
Description: Given relugolix

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triptorelin
Description: Given triptorelin
Study: NCT06168058

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Transcatheter Venography
Description: Venographic assessment of ovarian veins and internal iliac veins

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Transcatheter Venography
Description: Venographic assessment of ovarian veins and internal iliac veins

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral ovarian vein embolization
Description: Intervention will include sclerosis of pelvic varices and coil embolization of the bilateral ovarian veins.
Study: NCT05986721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGB101
Description: low-dose levetiracetam, 220 mg, extended release tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral tablet
Study: NCT04234386

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: GammaPod Radiation
Description: The basic design is a dose-escalation phase Ib study with 4 predefined dose levels. With this study treatment, participants will receive the dose level assigned treatment of radiation therapy before the lumpectomy surgery.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: GammaPod Radiation
Description: The basic design is a dose-escalation phase Ib study with 4 predefined dose levels. With this study treatment, participants will receive the dose level assigned treatment of radiation therapy before the lumpectomy surgery.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: GammaPod Radiation
Description: The basic design is a dose-escalation phase Ib study with 4 predefined dose levels. With this study treatment, participants will receive the dose level assigned treatment of radiation therapy before the lumpectomy surgery.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: GammaPod Radiation
Description: The basic design is a dose-escalation phase Ib study with 4 predefined dose levels. With this study treatment, participants will receive the dose level assigned treatment of radiation therapy before the lumpectomy surgery.
Study: NCT05827614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI-355
Description: Oral CHK1 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI-355
Description: Oral CHK1 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI-355
Description: Oral CHK1 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI-355
Description: Oral CHK1 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: EGFR Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Futibatinib
Description: FGFR1-4 Inhibitor
Study: NCT04205032

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test of the different devices integrated in cardiospace II
Description: The different devices included in CARDIOSPACE II will be tested~* Electrocardiogram~* Vascular Doppler~* LaserDoppler and iontophoresis~* Brachial blood pressure~* Continuous blood pressure recorded at the finger level~* Ultrasound~* Ambulatory Electrocardiogram / SAO2 (arterial oxygen saturation)
Study: NCT06463119

Intervention type: OTHER
Intervention: Collection of data in a registry
Description: The aim of this observational project is to document the immunogenicity and reactogenicity of vaccines given to immunocompromised patients and collect it in a registry.
Study: NCT05323929

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ESD
Description: Endoscopic Submucosal Dissection for early gastric cancer

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ESD
Description: Endoscopic Submucosal Dissection for early gastric cancer
Study: NCT05487469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymosin Alpha1
Description: Thymosin alpha 1, 1.6mg injection hypodermic (I.H), every 12 hours for 5 days at least during the ICU admission. The administration will be terminated any day during the treatment when the patient is deemed as qualified for ICU discharge or dead

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Blank Control
Description: the Control group did not receive Thymosin alpha 1 or any placebo.
Study: NCT05265988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Cabozantinib at initial dosage of 40 mg per day and continuation of androgen deprivation therapy
Study: NCT06009380

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy and Rehabilitation
Description: The control group will receive the usual post-operative care of stretching lower extremity strengthening balance exercises and activities of daily living recommendations. In addition to the program given to the control group, the dual task program will be given progressively to the study group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy and Rehabilitation
Description: The control group will receive the usual post-operative care of stretching lower extremity strengthening balance exercises and activities of daily living recommendations. In addition to the program given to the control group, the dual task program will be given progressively to the study group.
Study: NCT05091632

Intervention type: PROCEDURE
Intervention: Electroencephalography
Description: Undergo EEG

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study: NCT05887687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]P3
Description: 68Ga-P3 is injected intravenously with a dose of 0.06-0.08 mCi/kg.
Study: NCT05396495

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeurolyserXR
Description: Using the NeurolyserXR to non-invasively ablate the posterior sacral branches enervating the sacroiliac joint
Study: NCT05000775

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: G-Niib
Description: G-NiiB®, a patent-protected microbiome immunity formula, composed of naturally occurring food-grade bacteria approved by health authorities, has been developed by a group of CUHK gastroenterology experts.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04839926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5mg CY150112
Description: single oral CY150112 while fasting on day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.5mg CY150112
Description: single oral CY150112 while fasting on day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4.5mg CY150112
Description: single oral CY150112 while fasting on day 1.
Study: NCT05661357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disitamab Vedotin Combined With Fruquintinib
Description: Furquinotinib: 3mg, Qd, 28 days as a cycle. Vidicizumab: according to the instructions of Vidicizumab, d1, 2.5 mg/kg, intravenous drip (ivgtt)
Study: NCT06335173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sabirnetug
Description: Intravenous sabirnetug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sabirnetug
Description: Intravenous sabirnetug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sabirnetug
Description: Intravenous sabirnetug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous Placebo
Study: NCT06352424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 456906
Description: BI 456906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 456906
Description: BI 456906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 456906
Description: BI 456906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 456906
Description: BI 456906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1820237
Description: BI 1820237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1820237
Description: BI 1820237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1820237
Description: BI 1820237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1820237
Description: BI 1820237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for BI 1820237
Description: Placebo for BI 1820237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for BI 1820237
Description: Placebo for BI 1820237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for BI 1820237
Description: Placebo for BI 1820237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for BI 1820237
Description: Placebo for BI 1820237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for BI 456906
Description: Placebo for BI 456906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for BI 456906
Description: Placebo for BI 456906
Study: NCT06746142

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Deep inspiration breath hold radiotherapy
Description: Participants will be trained for 2-3 days for obtaining the desired breathing cycle by trained technologists. No extra equipment will be needed. At first, they will be assured and asked to relax. Then instructed to breath in and out twice followed by a slow, deep breath in to a comfortable higher level than normal and to hold it for at least 20 seconds then again breath normally. Once they are ready with expected breath holding, simulation will be done. Treatment will also be given in this breath holding position.
Study: NCT06352424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for BI 456906
Description: Placebo for BI 456906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for BI 456906
Description: Placebo for BI 456906
Study: NCT05672199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavaleukin alfa
Description: Subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavaleukin alfa
Description: Subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavaleukin alfa
Description: Subcutaneous (SC) injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SC injection
Study: NCT06746142

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Free breathing radiotherapy
Description: Patient will be advised for free breathing during simulation and treatment.
Study: NCT06746129

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: embryo transfer
Description: transfer of embryo(s) into the uterine cavity

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: embryo transfer
Description: transfer of embryo(s) into the uterine cavity
Study: NCT06746038

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extended Wear Hearing Aid
Description: Extended wear hearing aid means that the device is worn 24 hours per day, 7 days a week for months at a time. However, this study will only fit devices on participants for one testing session lasting 2 hours.
Study: NCT06374498

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OCT-NIRAF
Description: Subjects will be imaged with OCT-NIRAF research catheter during their clinically indicated coronary angiogram. In addition, the subject will also receive two Coronary Computed Tomography Angiography (CCTA) 12 months apart, and images will be analyzed.
Study: NCT06123663

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TTVA
Description: Intramuscular injection, 1 dose of 0.5ml inoculated on Day 0

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TT
Description: Intramuscular injection, 1 dose of 0.5ml inoculated on Day 0
Study: NCT04917809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erdafitinib
Description: Participants will receive erdafitinib at a dose of 6 mg orally once daily for the first 14 days (±3 days). Serum phosphate levels will be assessed on day 14 (±3 days) and the dose of erdafitinib may be lowered based on the serum phosphate level. Treatment with erdafitinib at a dose of 6 mg orally once daily, or at a lower dose level for another 14 days (±3 days) until the day of their standard-of-care TURBT/biopsy. Standard-of-care TURBT/biopsy will be performed after approximately 28 days (±5 days) from the start of treatment with erdafitinib, and biologic and pathologic tumor response will be assessed. All participants will then be followed up for recurrence or progression in accordance with the standard of care.
Study: NCT05165485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revefenacin
Description: Revefenacin 175 mcg administered once daily for 84 days via nebulization

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: Tiotropium 18 mcg administered once daily for 84 days via Spiriva HandiHaler®

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Revefenacin Placebo
Description: Placebo for Revefenacin administered once daily for 84 days via nebulization

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium Placebo
Description: Placebo for Tiotropium administered once daily for 84 days via Spiriva HandiHaler®
Study: NCT05067634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xcopri
Description: Age groups 12 to \<18 will enroll once dosing data is received from Cohort I of the PK analysis of YKP3089C039 study. Age groups 6 to \<12 will enroll once dosing data is received from Cohort IIa of the PK analysis of YKP3089C039 study. Age groups 4 to \<6 will enroll once dosing data is received from Cohort IIb of the PK analysis of YKP3089C039 study. Age groups 2 to \<4 will enroll once dosing data is received from Cohort III of the PK analysis of YKP3089C039 study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xcopri
Description: Age groups 12 to \<18 will enroll once dosing data is received from Cohort I of the PK analysis of YKP3089C039 study. Age groups 6 to \<12 will enroll once dosing data is received from Cohort IIa of the PK analysis of YKP3089C039 study. Age groups 4 to \<6 will enroll once dosing data is received from Cohort IIb of the PK analysis of YKP3089C039 study. Age groups 2 to \<4 will enroll once dosing data is received from Cohort III of the PK analysis of YKP3089C039 study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xcopri
Description: Age groups 12 to \<18 will enroll once dosing data is received from Cohort I of the PK analysis of YKP3089C039 study. Age groups 6 to \<12 will enroll once dosing data is received from Cohort IIa of the PK analysis of YKP3089C039 study. Age groups 4 to \<6 will enroll once dosing data is received from Cohort IIb of the PK analysis of YKP3089C039 study. Age groups 2 to \<4 will enroll once dosing data is received from Cohort III of the PK analysis of YKP3089C039 study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xcopri
Description: Age groups 12 to \<18 will enroll once dosing data is received from Cohort I of the PK analysis of YKP3089C039 study. Age groups 6 to \<12 will enroll once dosing data is received from Cohort IIa of the PK analysis of YKP3089C039 study. Age groups 4 to \<6 will enroll once dosing data is received from Cohort IIb of the PK analysis of YKP3089C039 study. Age groups 2 to \<4 will enroll once dosing data is received from Cohort III of the PK analysis of YKP3089C039 study.
Study: NCT05495087

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IHT Treatment
Description: IHT Treatment: IH exposure to 10% O2 for up to 5 min, interspersed with breathing room air recovery for up to 5 min, with up to 8 cycles/session, 3 sessions/week, for up to 12 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham-IHT Control
Description: Sham-IHT Control: Exposure to 21% O2 for up to 5 min, interspersed with breathing room air recovery for up to 5 min, with up to 8 cycles/session, 3 sessions/week, for up to 12 weeks.
Study: NCT06352333

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: supraclavicular ultrasound guided brachial plexus block
Description: two approaches of ultrasound guided supraclavicular brachial plexus block in upper limb surgery : the cornerpocket supraclavicular brachial plexus block and parasagittal supraclavicular brachial plexus block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: supraclavicular ultrasound guided brachial plexus block
Description: two approaches of ultrasound guided supraclavicular brachial plexus block in upper limb surgery : the cornerpocket supraclavicular brachial plexus block and parasagittal supraclavicular brachial plexus block
Study: NCT05967143

Intervention type: DEVICE
Intervention: SIRT
Description: Selective internal radiation therapy with SIR-Spheres Y90 resin microspheres.